Redmile Group
Latest statistics and disclosures from Redmile Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are KRYS, NRIX, FOLD, IMNM, KYMR, and represent 27.64% of Redmile Group's stock portfolio.
- Added to shares of these 9 stocks: BNTX (+$18M), Oruka Therapeutics (+$10M), ATXS, RGNX, PEN, ESTA, FDMT, ADCT, HOOK.
- Started 5 new stock positions in Oruka Therapeutics, BNTX, ATXS, HOOK, PEN.
- Reduced shares in these 10 stocks: KRYS (-$38M), FOLD (-$25M), BPMC (-$10M), KYMR (-$8.8M), REPL (-$8.6M), TRDA (-$8.0M), AKRO (-$6.5M), ISRG (-$6.5M), BSX, COGT.
- Sold out of its positions in TKNO, BPMC, TRDA, LAB, Hookipa Pharma Inc equity.
- Redmile Group was a net seller of stock by $-111M.
- Redmile Group has $1.7B in assets under management (AUM), dropping by 2.63%.
- Central Index Key (CIK): 0001425738
Tip: Access up to 7 years of quarterly data
Positions held by Redmile Group consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Redmile Group
Redmile Group holds 63 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Krystal Biotech (KRYS) | 8.7 | $148M | -20% | 810k | 182.03 |
|
| Nurix Therapeutics (NRIX) | 5.7 | $96M | -3% | 4.3M | 22.47 |
|
| Amicus Therapeutics (FOLD) | 5.2 | $88M | -22% | 8.2M | 10.68 |
|
| Immunome (IMNM) | 4.2 | $72M | 4.9M | 14.62 |
|
|
| Kymera Therapeutics (KYMR) | 3.9 | $66M | -11% | 1.4M | 47.33 |
|
| Zymeworks Del (ZYME) | 3.8 | $64M | -2% | 5.1M | 12.55 |
|
| Stoke Therapeutics (STOK) | 3.4 | $58M | 4.7M | 12.29 |
|
|
| Replimune Group (REPL) | 3.1 | $52M | -14% | 4.8M | 10.96 |
|
| Biohaven (BHVN) | 3.0 | $52M | -4% | 1.0M | 49.97 |
|
| Regenxbio Inc equity us cm (RGNX) | 3.0 | $51M | +7% | 4.9M | 10.49 |
|
| Igm Biosciences (IGMS) | 3.0 | $51M | 3.1M | 16.54 |
|
|
| Adc Therapeutics Sa SHS (ADCT) | 2.9 | $49M | +2% | 16M | 3.15 |
|
| Cogent Biosciences (COGT) | 2.9 | $48M | -6% | 4.5M | 10.80 |
|
| Fate Therapeutics (FATE) | 2.7 | $46M | 13M | 3.50 |
|
|
| Livanova SHS (LIVN) | 2.7 | $46M | -5% | 875k | 52.54 |
|
| Scholar Rock Hldg Corp (SRRK) | 2.5 | $42M | -3% | 5.2M | 8.01 |
|
| Neurogene (NGNE) | 2.4 | $41M | -4% | 964k | 41.96 |
|
| Akero Therapeutics (AKRO) | 2.3 | $40M | -14% | 1.4M | 28.69 |
|
| Beam Therapeutics (BEAM) | 2.3 | $40M | -5% | 1.6M | 24.50 |
|
| Augmedix (AUGX) | 2.3 | $39M | 16M | 2.35 |
|
|
| Annexon (ANNX) | 2.2 | $38M | 6.4M | 5.92 |
|
|
| Catalent (CTLT) | 2.1 | $36M | 596k | 60.57 |
|
|
| Pliant Therapeutics (PLRX) | 2.1 | $36M | 3.2M | 11.21 |
|
|
| Silence Therapeutics Ads (SLN) | 2.0 | $35M | -5% | 1.9M | 18.18 |
|
| Keros Therapeutics (KROS) | 1.9 | $32M | 553k | 58.07 |
|
|
| Absci Corp (ABSI) | 1.9 | $32M | 8.3M | 3.82 |
|
|
| Boston Scientific Corporation (BSX) | 1.6 | $28M | -15% | 331k | 83.80 |
|
| Celldex Therapeutics Com New (CLDX) | 1.3 | $22M | -8% | 657k | 33.99 |
|
| Ideaya Biosciences (IDYA) | 1.3 | $22M | -10% | 681k | 31.68 |
|
| Shattuck Labs (STTK) | 1.2 | $20M | 5.6M | 3.49 |
|
|
| Biontech Se Sponsored Ads (BNTX) | 1.1 | $18M | NEW | 155k | 118.77 |
|
| Immunovant (IMVT) | 1.1 | $18M | -10% | 642k | 28.51 |
|
| 4d Molecular Therapeutics In (FDMT) | 0.8 | $14M | +17% | 1.3M | 10.81 |
|
| Intuitive Surgical Com New (ISRG) | 0.8 | $13M | -32% | 27k | 491.27 |
|
| Stryker Corporation (SYK) | 0.7 | $12M | -17% | 33k | 361.26 |
|
| 89bio (ETNB) | 0.7 | $12M | -10% | 1.6M | 7.40 |
|
| Ardelyx (ARDX) | 0.7 | $11M | -11% | 1.7M | 6.89 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.7 | $11M | +22% | 262k | 43.27 |
|
| Oruka Therapeutics | 0.6 | $10M | NEW | 412k | 24.51 |
|
| Prime Medicine (PRME) | 0.5 | $8.0M | 2.1M | 3.87 |
|
|
| Alx Oncology Hldgs (ALXO) | 0.4 | $7.0M | -4% | 3.8M | 1.82 |
|
| Nuvation Bio Com Cl A (NUVB) | 0.4 | $6.9M | 3.0M | 2.29 |
|
|
| Verve Therapeutics (VERV) | 0.4 | $6.7M | -5% | 1.4M | 4.84 |
|
| Repare Therapeutics Ord (RPTX) | 0.4 | $6.7M | 1.9M | 3.44 |
|
|
| Ac Immune Sa SHS (ACIU) | 0.4 | $6.4M | -6% | 1.7M | 3.78 |
|
| Cytokinetics Com New (CYTK) | 0.3 | $5.1M | -13% | 97k | 52.80 |
|
| Ventyx Biosciences (VTYX) | 0.3 | $4.6M | -2% | 2.1M | 2.18 |
|
| Stereotaxis Com New (STXS) | 0.3 | $4.3M | 2.1M | 2.04 |
|
|
| Atara Biotherapeutics Com New (ATRA) | 0.2 | $3.7M | 452k | 8.13 |
|
|
| Boundless Bio (BOLD) | 0.2 | $3.6M | 1.0M | 3.47 |
|
|
| Lava Therapeutics Nv SHS (LVTX) | 0.2 | $3.4M | 2.1M | 1.66 |
|
|
| Astria Therapeutics (ATXS) | 0.2 | $3.4M | NEW | 311k | 11.01 |
|
| Adagio Therapeutics (IVVD) | 0.2 | $3.1M | 3.1M | 1.02 |
|
|
| Xeris Pharmaceuticals (XERS) | 0.2 | $3.0M | 1.0M | 2.85 |
|
|
| Gritstone Oncology Ord (GRTS) | 0.2 | $2.9M | -3% | 4.9M | 0.58 |
|
| Penumbra (PEN) | 0.2 | $2.7M | NEW | 14k | 194.31 |
|
| Cabaletta Bio (CABA) | 0.1 | $2.1M | 443k | 4.72 |
|
|
| Allakos (ALLK) | 0.1 | $2.0M | 3.1M | 0.65 |
|
|
| Achilles Therapeutics Sponsored Ads (ACHL) | 0.1 | $1.6M | 1.6M | 1.02 |
|
|
| Allovir (ALVR) | 0.1 | $1.5M | 1.9M | 0.81 |
|
|
| Rapt Therapeutics (RAPT) | 0.1 | $1.0M | -5% | 505k | 2.01 |
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.0 | $680k | 716k | 0.95 |
|
|
| Hookipa Pharma Com New (HOOK) | 0.0 | $457k | NEW | 106k | 4.30 |
|
Past Filings by Redmile Group
SEC 13F filings are viewable for Redmile Group going back to 2010
- Redmile Group 2024 Q3 filed Nov. 14, 2024
- Redmile Group 2024 Q2 filed Aug. 14, 2024
- Redmile Group 2024 Q1 filed May 15, 2024
- Redmile Group 2023 Q4 filed Feb. 14, 2024
- Redmile Group 2023 Q3 filed Nov. 14, 2023
- Redmile Group 2023 Q2 filed Aug. 14, 2023
- Redmile Group 2023 Q1 filed May 15, 2023
- Redmile Group 2022 Q4 filed Feb. 14, 2023
- Redmile Group 2022 Q3 filed Nov. 14, 2022
- Redmile Group 2022 Q2 filed Aug. 15, 2022
- Redmile Group 2022 Q1 filed May 16, 2022
- Redmile Group 2021 Q4 filed Feb. 14, 2022
- Redmile Group 2021 Q3 filed Nov. 15, 2021
- Redmile Group 2021 Q2 filed Aug. 16, 2021
- Redmile Group 2021 Q1 filed May 17, 2021
- Redmile Group 2020 Q4 filed Feb. 16, 2021